Department of Internal Medicine, Oregon Health and Science University, Portland, Oregon.
School of Medicine, Oregon Health and Science University, Portland, Oregon.
Eur J Haematol. 2020 Feb;104(2):79-87. doi: 10.1111/ejh.13348. Epub 2019 Dec 16.
Clinically significant bleeding can occur as a consequence of surgery, trauma, obstetric complications, anticoagulation, and a wide variety of disorders of hemostasis. As the causes of bleeding are diverse and not always immediately apparent, the availability of a safe, effective, and non-specific hemostatic agent is vital in a wide range of clinical settings, with antifibrinolytic agents often utilized for this purpose. Tranexamic acid (TXA) is one of the most commonly used and widely researched antifibrinolytic agents; its role in postpartum hemorrhage, menorrhagia, trauma-associated hemorrhage, and surgical bleeding has been well defined. However, the utility of TXA goes beyond these common indications, with accumulating data suggesting its ability to reduce bleeding and improve clinical outcomes in the face of many different hemostatic challenges, without a clear increase in thrombotic risk. Herein, we review the literature and provide practical suggestions for clinical use of TXA across a broad spectrum of bleeding disorders.
临床显著出血可由手术、创伤、产科并发症、抗凝治疗以及广泛的止血功能障碍引起。由于出血的原因多种多样,并不总是立即显现,因此在广泛的临床环境中,安全、有效、非特异性的止血剂的可用性至关重要,为此通常使用抗纤维蛋白溶解剂。氨甲环酸(TXA)是最常用和广泛研究的抗纤维蛋白溶解剂之一;其在产后出血、月经过多、与创伤相关的出血和手术出血中的作用已得到明确界定。然而,TXA 的用途不仅限于这些常见的适应症,越来越多的数据表明,它能够在面对许多不同的止血挑战时减少出血并改善临床结局,而不会明显增加血栓形成的风险。在此,我们回顾文献,并为 TXA 在广泛的出血性疾病中的临床应用提供实用建议。